210 related articles for article (PubMed ID: 23937566)
1. Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.
Martínez S; Pérez L; Galmarini CM; Aracil M; Tercero JC; Gago F; Albella B; Bueren JA
Br J Pharmacol; 2013 Oct; 170(4):871-82. PubMed ID: 23937566
[TBL] [Abstract][Full Text] [Related]
2. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin.
Casado JA; Río P; Marco E; García-Hernández V; Domingo A; Pérez L; Tercero JC; Vaquero JJ; Albella B; Gago F; Bueren JA
Mol Cancer Ther; 2008 May; 7(5):1309-18. PubMed ID: 18483318
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
5. Assessment of mitomycin C sensitivity in Fanconi anemia complementation group C gene (Fac) knock-out mouse cells.
Otsuki T; Wang J; Demuth I; Digweed M; Liu JM
Int J Hematol; 1998 Apr; 67(3):243-8. PubMed ID: 9650445
[TBL] [Abstract][Full Text] [Related]
6. Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks.
Mason JM; Sekiguchi JM
Hum Mol Genet; 2011 Jul; 20(13):2549-59. PubMed ID: 21478198
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector.
Walsh CE; Nienhuis AW; Samulski RJ; Brown MG; Miller JL; Young NS; Liu JM
J Clin Invest; 1994 Oct; 94(4):1440-8. PubMed ID: 7929819
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
Gallmeier E; Hucl T; Brody JR; Dezentje DA; Tahir K; Kasparkova J; Brabec V; Bachman KE; Kern SE
Cancer Res; 2007 Mar; 67(5):2169-77. PubMed ID: 17332347
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow failure in the Fanconi anemia group C mouse model after DNA damage.
Carreau M; Gan OI; Liu L; Doedens M; McKerlie C; Dick JE; Buchwald M
Blood; 1998 Apr; 91(8):2737-44. PubMed ID: 9531583
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
[TBL] [Abstract][Full Text] [Related]
11. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
12. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
[TBL] [Abstract][Full Text] [Related]
13. DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.
Shukla P; Solanki A; Ghosh K; Vundinti BR
Eur J Haematol; 2013 Nov; 91(5):381-93. PubMed ID: 23859405
[TBL] [Abstract][Full Text] [Related]
14. Fanconi's anemia cell lines show distinct mechanisms of cell death in response to mitomycin C or agonistic anti-Fas antibodies.
Clarke AA; Gibson FM; Scott J; Myatt N; Rutherford TR
Haematologica; 2004 Jan; 89(1):11-20. PubMed ID: 14754601
[TBL] [Abstract][Full Text] [Related]
15. A functionally active retrovirus vector for gene therapy in Fanconi anemia group C.
Walsh CE; Grompe M; Vanin E; Buchwald M; Young NS; Nienhuis AW; Liu JM
Blood; 1994 Jul; 84(2):453-9. PubMed ID: 7517716
[TBL] [Abstract][Full Text] [Related]
16. The Drosophila S3 multifunctional DNA repair/ribosomal protein protects Fanconi anemia cells against oxidative DNA damaging agents.
Kelley MR; Tritt R; Xu Y; New S; Freie B; Clapp DW; Deutsch WA
Mutat Res; 2001 Mar; 485(2):107-19. PubMed ID: 11182542
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells.
Rathbun RK; Faulkner GR; Ostroski MH; Christianson TA; Hughes G; Jones G; Cahn R; Maziarz R; Royle G; Keeble W; Heinrich MC; Grompe M; Tower PA; Bagby GC
Blood; 1997 Aug; 90(3):974-85. PubMed ID: 9242526
[TBL] [Abstract][Full Text] [Related]
18. Fanconi anemia pathway--the way of DNA interstrand cross-link repair.
Yao CJ; Du W; Zhang Q; Zhang F; Zeng F; Chen FP
Pharmazie; 2013 Jan; 68(1):5-11. PubMed ID: 23444773
[TBL] [Abstract][Full Text] [Related]
19. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
[TBL] [Abstract][Full Text] [Related]
20. Evidence for subcomplexes in the Fanconi anemia pathway.
Medhurst AL; Laghmani el H; Steltenpool J; Ferrer M; Fontaine C; de Groot J; Rooimans MA; Scheper RJ; Meetei AR; Wang W; Joenje H; de Winter JP
Blood; 2006 Sep; 108(6):2072-80. PubMed ID: 16720839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
